Spinal Muscular Atrophy (SMA)
A rare neuromuscular disorder
We launched a partnership with Roche Pharma (Switzerland) Ltd in Spinal Muscular Atrophy (SMA), a rare neuromuscular disorder. Under this partnership, we are working together to improve the quality of life of people living with SMA. As care is shifting from hospital to home, we believe that continuous data collection by non-invasive ambient and wearable sensors, coupled with easy visualization, empowers better monitoring of the patients’ condition. As a result, their care and well-being can be optimized faster and more easily. The prospects for AI are also enormous in SMA, with the potential to detect early and perhaps even predict sudden health deteriorations, respiration issues or infections (e.g. pneumonia) or falls.